The central goal of this program is to understand the therapeutic utility of novel strategies to stimulate Tumor cell killing by the immune system. The Imaging Core will play multiple diverse roles within this program. In summary, our primary roles will be : careful analysis of cellular and molecular processes associated with apoptosis, characterization and quantification of cell types within tumors, examination of protein expression during cell death, examination of cell-cell interactions in vitro, quantitative analysis of protein expression by individual cells within tissues, and measurement of the levels and patterns of expression of chemokines and cell-type markers in tumors and tumor explants. These studies will employ the full array of current light, and potentially, electron microscopic methods including: single and multicolor fluorescence microscopy, laser confocal microscopy, live cell imaging, transmission electron microscopy and computer-aided morphometric analyses. The Center for Biologic Imaging, in which this core (B1) service will be performed, is designed for the purpose of providing state of the art microscopic technologies to its users. It is equipped to perform a continuum of optical methods including all types of light and electron microscopy essential to this Program Project. Within the scope of this project at the light microscopic level these methods include: histology, immuno-histology, live cell and in situ hybridization methods. The Core will be used extensively by all projects. Core B2 will provide in situ analysis services to all projects, including: generation and sequence confirmation of gene-specific cDNA templates for probe synthesis;in situ hybridization with radioactive cRNA probes and autoradiography;combined in situ hybridization and immunohistochemical staining;and image capture, analysis, and documentation for data sharing and publication. These analysis services will provide integrated data on chemokine expression profiles and producer cells in tumor-containing tissues provided by all projects. Core B3, will act to provide whole animal MRI services as needed in each project. In the previous submission this core was very highly regarded as such changes have been kept to a minimum and only reflect continued interaction and productivity between the core and the project Pis

Public Health Relevance

(Seeinstructions):

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA132714-05
Application #
8469295
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
5
Fiscal Year
2013
Total Cost
$199,082
Indirect Cost
$67,368
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Okada, Hideho; Butterfield, Lisa H; Hamilton, Ronald L et al. (2015) Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin Cancer Res 21:286-94
Guo, Z S; Bartlett, D L (2014) Oncolytic viruses as platform for multimodal cancer therapeutics: a promising land. Cancer Gene Ther 21:261-3
Ohkuri, Takayuki; Ghosh, Arundhati; Kosaka, Akemi et al. (2014) STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol Res 2:1199-208
Kosaka, Akemi; Ohkuri, Takayuki; Okada, Hideho (2014) Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells. Cancer Immunol Immunother 63:847-57
Hamilton, Ronald; Krauze, Michal; Romkes, Marjorie et al. (2013) Pathologic and gene expression features of metastatic melanomas to the brain. Cancer 119:2737-46
Kohanbash, Gary; McKaveney, Kayla; Sakaki, Masashi et al. (2013) GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-*. Cancer Res 73:6413-23
Okada, Hideho; Scheurer, Michael E; Sarkar, Saumendra N et al. (2013) Integration of epidemiology, immunobiology, and translational research for brain tumors. Ann N Y Acad Sci 1284:17-23
Sampath, Padma; Li, Jun; Hou, Weizhou et al. (2013) Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects. Mol Ther 21:620-8
Yeung, Jacky T; Hamilton, Ronald L; Ohnishi, Koji et al. (2013) LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma. Clin Cancer Res 19:1816-26
Bartlett, David L; Liu, Zuqiang; Sathaiah, Magesh et al. (2013) Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer 12:103

Showing the most recent 10 out of 37 publications